| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | RVMD | Common Stock | Purchase | $5.1M | +232K | +18.98% | $22.00 | 1.45M | Mar 7, 2023 | By Nextech Crossover I SCSP | F1 |
| transaction | RVMD | Common Stock | Purchase | $7M | +318K | +106.06% | $22.00 | 618K | Mar 7, 2023 | By Nextech VI Oncology SCSp | F2 |
| transaction | RVMD | Common Stock | Purchase | $1.92M | +93.8K | +6.46% | $20.43 | 1.55M | Mar 10, 2023 | By Nextech Crossover I SCSP | F1, F3 |
| transaction | RVMD | Common Stock | Purchase | $129K | +6.2K | +0.4% | $20.85 | 1.55M | Mar 10, 2023 | By Nextech Crossover I SCSP | F1, F4 |
| holding | RVMD | Common Stock | 2.67M | Mar 7, 2023 | By Nextech V Oncology S.C.S., SICAV-SIF | F5 |
| Id | Content |
|---|---|
| F1 | Nextech Invest AG is the investment advisor of Nextech Crossover I SCSP ("Nextech Crossover"). The reporting person is a managing member at Nextech Invest AG and may therefore be deemed to be the beneficial owner of shares held by Nextech Crossover. The reporting person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. |
| F2 | Nextech Invest AG is the investment advisor of Nextech VI Oncology SCSp ("Nextech VI"). The reporting person is a managing member at Nextech Invest AG and may therefore be deemed to be the beneficial owner of shares held by Nextech VI. The reporting person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. |
| F3 | The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $19.81 to $20.81 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. |
| F4 | The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $20.82 to $20.88 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote, |
| F5 | Nextech Invest AG is the investment advisor of Nextech V Oncology S.C.S., SICAV-SIF ("Nextech V"). The reporting person is a managing member at Nextech Invest AG and may therefore be deemed to be the beneficial owner of shares held by Nextech V. The reporting person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. |